Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 59%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is a promising company with an expected increase in price target due to strong growth potential in the rapidly expanding blood-based oncology test market, reaffirmed by analysts with a Buy rating and named as their top pick for 2026 with upcoming catalysts, expansion plans, and a new tissue-informed test. Despite potential competition and required additional funding, Guardant's inclusion in cancer screening guidelines and strong gross margin expectations are positive factors. Questions surrounding their contract with UNH may raise concerns, but overall, their track record of success and planned growth initiatives make them a favorable choice for investors.

Bears say

Guardant Health is a leader in liquid-based cancer tests, however, there are a number of potential risks that could negatively impact its success. These include potential competition in the MRD testing market, potential challenges in gaining reimbursement for its tests, and potential legal risks in an increasingly competitive marketplace. Additionally, the recent inclusion of Guardant's Shield CRC test in NCCN and ACS guidelines may bring short-term momentum, but could also lead to challenges in signing commercial health plan contracts and gaining support from healthcare systems.

GH has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 59% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 22 analysts, GH has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $181.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $181.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.